Created: November 18, 2021 09:21 AM
Pfizer and Merck are both touting their antiviral drugs still waiting for FDA approval as game-changers for saving lives affected by COVID-19. How do they work, and what about monoclonal antibody treatment by Lilly and Regeneron? Where do they fit in the treatment game? How does all this play out with vaccines? Happy to have Dr. Joe Bertino back, a clinical pharmacologist, he's the editor of the Journal of Clinical Pharmacology and has more than 30 years of experience in the area of drug development and clinical pharmacology.
Copyright 2021 - WNYT-TV, LLC A Hubbard Broadcasting Company